ABPO

distress 5/10 · elevated risk

$0.19-5%today-98% from 52w high

abpro.co1 employeesFounded 2004Burlington, MABiotechnology

Lead: HER2-positive cancers

Revenue

pre-revenue

Liquidity

$5M

Runway

0.8 yrs

Shares 1y

-93%

Price & events

-93.3% over 6M

CatalystRating changeDilutionFinancingdashed = today

-5.2%

-2.8%

-7.4%

+35.9%

-92.5%

-97.8%

-99.9%

—

-99.9%

All

Overview

Market Cap: $1.15M
Volume: 41
52 Week Range: $0.10 – $9.69
Total Shares: 5.90M
Float Shares: 4.95M
Short %: 2.56%
% Held by Insiders: 16.09%
% Held by Institutions: 0.01%
RVOL: 0.00x
Beta: 0.15

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 5

anticipated in 2026Guided 40%trial initiationsecondaryPhase 1ABP-102 · First-in-human trial anticipatedSEC 8-K
1H 2026trial initiationsecondaryPhase 1ABP-102/CT-P72 · Phase 1 trial anticipated to begin in first half of 2026SEC 8-K
2026-01-06fda agreementABP-102/CT-P72 · FDA cleared IND for ABP-102/CT-P72SEC 8-K
December 15, 2025regulatory submissionFiled (NDA/BLA)ABP-102/CT-P72 · IND submitted to FDA for phase 1 trialSEC 8-K
Friday, November 7, 2025, 9:00 a.m. – 6:35 p.m. (ET)conferencedata presentationsecondaryCT-P72/ABP-102 · Presentation of preclinical data for CT-P72/ABP-102 at SITC 2025.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 5,896,048 · 0 offerings/1y · 0 PIPEs

none

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — HER2-positive cancers

ABPWWAbpro Holdings, Inc.$67,805 · D4

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.